Navigation Links
QLT announces Visudyne(R) sales for fourth quarter and fiscal year 2008
Date:1/12/2009

VANCOUVER, Jan. 12 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI; TSX:QLT) today announced global Visudyne(R) (verteporfin) sales of US$30.6 million for the quarter and $141.9 million for the full year ended December 31, 2008. Visudyne sales for the fourth quarter declined by 32.7% over the same quarter in 2007 and the full year represented a decrease of 34.0% from annual sales in 2007. Sales in the U.S. for the quarter were $8.0 million, down 20.0% from the prior-year fourth quarter while sales outside the U.S. were $22.6 million, down 36.3% from the same quarter of the prior year.

QLT will release its full financial results on Thursday, February 19, 2009, at 7:30 AM Eastern Time (ET).

A full explanation of how QLT determines and recognizes revenue resulting from Visudyne sales is set out in the financial statements contained in the periodic reports on Forms 10-Q and 10-K, under the heading "Significant Accounting Policies - Revenue Recognition." Visudyne sales are product sales by Novartis under its agreement with QLT.

Conference call information

QLT Inc. will hold an investor conference call to discuss fourth quarter and year end 2008 results on Thursday, February 19, 2009 at 8:30 a.m. EST (5:30 a.m. PST). The call will be broadcast live via the Internet at www.qltinc.com. To participate on the call, please dial 1-800-319-4610 (North America) or 604-638-5340 (International) before 8:30 a.m. EST. A replay of the call will be available via the Internet and also via telephone at 1-800-319-6413 (North America) or 604-638-9010 (International), access code 7157, followed by the "number" sign.

About QLT

QLT Inc. is a global biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies. Our research and development efforts are focused on pharmaceutical products in the field of ophthalmology. In addition, we utilize three unique technology platforms, photodynamic therapy, Atrigel(R) and punctal plugs with drugs, to create products such as Visudyne(R) and Eligard(R) and future product opportunities. For more information, visit our web site at www.qltinc.com.

    QLT Plug Delivery, Inc. is a wholly-owned subsidiary of QLT Inc.
    Atrigel is a registered trademark of QLT USA, Inc.
    Visudyne is a registered trademark of Novartis AG.
    Eligard is a registered trademark of Sanofi-aventis.

    QLT Inc. is listed on The NASDAQ Stock Market under the trading symbol
"QLTI" and on The Toronto Stock Exchange under the trading symbol "QLT."


'/>"/>
SOURCE QLT Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Ranir, LLC Announces the Acquisition of Placontrol, Inc.
2. Varian Medical Systems Announces Net Orders Growth Estimates for the First Quarter of Fiscal Year 2009
3. Mindray Announces Preliminary 2008 Operating Results
4. BD Announces FDA 510(k) Clearance of Novel Molecular Assay to Diagnose Clostridium difficile Infections
5. Alsius Corporation Pre-Announces Record Fourth Quarter and Full Year 2008 Revenue
6. Allen Technologies, Inc. Announces Vigo Interactive Communication and Education System Agreement with Saint John's Health Center, Santa Monica, California
7. Rubicon Genomics Announces a Licensing Agreement With Abbott to Develop and Commercialize DNA Methylation Cancer Tests
8. Oleen Pinnacle Announces Acquisition of Partners in Health Systems
9. Thermage, Inc. Announces Name Change to Solta Medical, Inc.
10. Miami Beach Real Estate Attorney Announces Specialized Legal and Realty Services for Clients Buying Bank-Owned Luxury Miami Beach Condos
11. Genomma Lab Announces Initiation of Stock Repurchase Fund
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... , ... February 26, 2017 , ... Miro is the ... sound and video system brings songs, movies, TV shows and much more apps for ... clear, high-definition sound. An immersive view of 1280 x 720 provides crisp images with ...
(Date:2/27/2017)... ... 27, 2017 , ... POUGHKEEPSIE, N. Y. – Peer-reviewed guidelines from the International ... the Center for Disease Control ( CDC ) and Infectious Diseases Society of America ... M.D. has compiled into a single volume a compelling argument that the disease does ...
(Date:2/27/2017)... ... February 27, 2017 , ... Texas based retail electric ... Discount Power's RCE (Residential Customer Equivalent) count exceeds 150,000. , Discount ... 800 customers and 2,250 RCEs at the time of acquisition. In the three ...
(Date:2/27/2017)... , ... February 27, 2017 , ... ... and alcohol treatment programs in British Columbia, Canada, at https://www.sunshinecoasthealthcentre.ca/ , is ... team. The new hire, Mackenzie Alsager, showcases the Centre's commitment to innovation in ...
(Date:2/27/2017)... ... February 27, 2017 , ... Silicon Valley Hair ... announce a new informational post on robotic hair transplantation. San Francisco residents may ... transplant and Follicular Unit Transplantation (FUT) can sound similar. Either treatment can be ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... Feb. 27, 2017  CTI BioPharma Corp. (CTI BioPharma) (NASDAQ ... Craig , M.D., Ph.D., as President and Chief Executive Officer ... 20, 2017. Dr. Craig succeeds Richard Love , interim ... company,s Board of Directors.  Dr. Craig has over 20 years ... the US and Europe . ...
(Date:2/27/2017)... N.J. and PETACH TIKVAH, Israel ... Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult ... appointments of June S. Almenoff , M.D., Ph.D., ... to its Board of Directors.  "Dr. ... executives whose appointments come at an exciting time for ...
(Date:2/27/2017)... , Feb 27, 2017 Period October – December ... Operating result amounted to SEK -16.4 (-6.4) million ... per share (-0.22) before and after dilution Cash flow from ... ... to SEK 0.4 (0.4) million Operating result amounted to SEK ...
Breaking Medicine Technology: